Carregant...
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels
The dioxonapthoimidazolium YM155 is a survivin suppressant which has been investigated as an anticancer agent in clinical trials. Here, we investigated its growth inhibitory properties on a panel of immortalized and patient derived renal cell carcinoma (RCC) cell lines which were either deficient in...
Guardat en:
| Publicat a: | PLoS One |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459331/ https://ncbi.nlm.nih.gov/pubmed/28582447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0178168 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|